Hematology Phase 3 Deal Benchmarks — China

Understanding Hematology Deal Benchmarks at Phase 3

Phase 3 Hematology licensing deals in China territory command a median upfront payment of $242M, with values ranging from $154M at the low end to $350M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the hematology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $615M to $1.0B, with a median of $831M. Royalty rates for hematology assets at this stage typically fall between 6.2% and 11.3% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The China territory applies a 0.12x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating china rights should calibrate upfront expectations and milestone structures accordingly.